TargetBeta
NPY2R
neuropeptide Y receptor Y2 · Neuropeptide Y receptors
2 programs in company-led studies act on NPY2R, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| BI 3034701 | Boehringer Ingelheim | phase 2 | 64 running | GIPR, GLP1R | the company's pipeline |
| nisotirostide | Eli Lilly | phase 2 | 41 running | – | a judged reading |
Conditions their studies are in
- Obesity, 2 programs
- Diabetes Mellitus, Type 2, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 15, 2026BI 3034701 · Boehringer Ingelheim · phase 2 · NCT07837648
- May 2027nisotirostide · Eli Lilly · phase 2 · NCT06897475
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.